FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003321101> ?p ?o ?g. }

• W3003321101 endingPage "e001042" @default.
• W3003321101 startingPage "e001042" @default.
• W3003321101 abstract "Objective To describe the efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in a post-hoc analysis of randomised controlled trials. Methods Data were collected from patients in seven tofacitinib studies: six phase III (four RA, two PsA) and one phase II study (AS), and grouped into five analysis populations based on rheumatic disease diagnosis and category of prior inadequate response (IR) to treatment: conventional synthetic disease-modifying antirheumatic drugs-IR (RA and PsA), tumour necrosis factor inhibitors-IR (RA and PsA), or non-steroidal anti-inflammatory drugs-IR (AS). Only patients who received tofacitinib 5 or 10 mg twice daily or placebo were included. Pain assessments included: Patient’s Assessment of Arthritis Pain, Short-Form Health Survey 36v2 Question (Q)7 and Bodily Pain domain, Ankylosing Spondylitis Quality of Life Q9 and Q14, EuroQol Five Dimensions Pain/Discomfort dimension and Bath Ankylosing Spondylitis Disease Activity Index Q2 and Q3. Data were reported to month 6 (placebo to month 3) in the RA and PsA populations, and week 12 (tofacitinib and placebo) in the AS population. Results Overall, 3330 patients were included in this analysis. In the RA and PsA populations, pain improvements in tofacitinib-treated patients compared with placebo were observed at the earliest time point assessed and at month 3 (maintained to month 6). In the AS population, pain improvements compared with placebo were observed at week 12. Conclusion Tofacitinib was associated with rapid and sustained improvements across multiple pain measures in patients with inflammatory rheumatic musculoskeletal diseases." @default.
• W3003321101 created "2020-02-07" @default.
• W3003321101 creator A5004934558 @default.
• W3003321101 creator A5008763926 @default.
• W3003321101 creator A5014427334 @default.
• W3003321101 creator A5018282952 @default.
• W3003321101 creator A5060125727 @default.
• W3003321101 creator A5064863811 @default.
• W3003321101 creator A5065176585 @default.
• W3003321101 creator A5071482630 @default.
• W3003321101 creator A5074629207 @default.
• W3003321101 creator A5081778211 @default.
• W3003321101 creator A5087471106 @default.
• W3003321101 date "2020-02-01" @default.
• W3003321101 modified "2023-09-30" @default.
• W3003321101 title "Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis" @default.
• W3003321101 cites W1560520727 @default.
• W3003321101 cites W1807077095 @default.
• W3003321101 cites W1957937187 @default.
• W3003321101 cites W2035320881 @default.
• W3003321101 cites W2042571430 @default.
• W3003321101 cites W2063265278 @default.
• W3003321101 cites W2069302785 @default.
• W3003321101 cites W2070458153 @default.
• W3003321101 cites W2071782474 @default.
• W3003321101 cites W2083180635 @default.
• W3003321101 cites W2090233921 @default.
• W3003321101 cites W2091855592 @default.
• W3003321101 cites W2102092354 @default.
• W3003321101 cites W2126477323 @default.
• W3003321101 cites W2128457788 @default.
• W3003321101 cites W2149447280 @default.
• W3003321101 cites W2152348310 @default.
• W3003321101 cites W2153836018 @default.
• W3003321101 cites W2159106700 @default.
• W3003321101 cites W2164858045 @default.
• W3003321101 cites W2168645087 @default.
• W3003321101 cites W2195835569 @default.
• W3003321101 cites W2235168239 @default.
• W3003321101 cites W2329207709 @default.
• W3003321101 cites W2473786944 @default.
• W3003321101 cites W2512318275 @default.
• W3003321101 cites W2554626374 @default.
• W3003321101 cites W2572897530 @default.
• W3003321101 cites W2610917967 @default.
• W3003321101 cites W2766717228 @default.
• W3003321101 cites W2766846920 @default.
• W3003321101 cites W997725819 @default.
• W3003321101 doi "https://doi.org/10.1136/rmdopen-2019-001042" @default.
• W3003321101 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6999680" @default.
• W3003321101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32396519" @default.
• W3003321101 hasPublicationYear "2020" @default.
• W3003321101 type Work @default.
• W3003321101 sameAs 3003321101 @default.
• W3003321101 citedByCount "18" @default.
• W3003321101 countsByYear W30033211012020 @default.
• W3003321101 countsByYear W30033211012021 @default.
• W3003321101 countsByYear W30033211012022 @default.
• W3003321101 countsByYear W30033211012023 @default.
• W3003321101 crossrefType "journal-article" @default.
• W3003321101 hasAuthorship W3003321101A5004934558 @default.
• W3003321101 hasAuthorship W3003321101A5008763926 @default.
• W3003321101 hasAuthorship W3003321101A5014427334 @default.
• W3003321101 hasAuthorship W3003321101A5018282952 @default.
• W3003321101 hasAuthorship W3003321101A5060125727 @default.
• W3003321101 hasAuthorship W3003321101A5064863811 @default.
• W3003321101 hasAuthorship W3003321101A5065176585 @default.
• W3003321101 hasAuthorship W3003321101A5071482630 @default.
• W3003321101 hasAuthorship W3003321101A5074629207 @default.
• W3003321101 hasAuthorship W3003321101A5081778211 @default.
• W3003321101 hasAuthorship W3003321101A5087471106 @default.
• W3003321101 hasBestOaLocation W30033211011 @default.
• W3003321101 hasConcept C126322002 @default.
• W3003321101 hasConcept C142724271 @default.
• W3003321101 hasConcept C204787440 @default.
• W3003321101 hasConcept C27081682 @default.
• W3003321101 hasConcept C2776233030 @default.
• W3003321101 hasConcept C2776260265 @default.
• W3003321101 hasConcept C2777077863 @default.
• W3003321101 hasConcept C2777402515 @default.
• W3003321101 hasConcept C2777575956 @default.
• W3003321101 hasConcept C2778886723 @default.
• W3003321101 hasConcept C2779650986 @default.
• W3003321101 hasConcept C2908647359 @default.
• W3003321101 hasConcept C71924100 @default.
• W3003321101 hasConcept C99454951 @default.
• W3003321101 hasConceptScore W3003321101C126322002 @default.
• W3003321101 hasConceptScore W3003321101C142724271 @default.
• W3003321101 hasConceptScore W3003321101C204787440 @default.
• W3003321101 hasConceptScore W3003321101C27081682 @default.
• W3003321101 hasConceptScore W3003321101C2776233030 @default.
• W3003321101 hasConceptScore W3003321101C2776260265 @default.
• W3003321101 hasConceptScore W3003321101C2777077863 @default.
• W3003321101 hasConceptScore W3003321101C2777402515 @default.
• W3003321101 hasConceptScore W3003321101C2777575956 @default.
• W3003321101 hasConceptScore W3003321101C2778886723 @default.
• W3003321101 hasConceptScore W3003321101C2779650986 @default.
• W3003321101 hasConceptScore W3003321101C2908647359 @default.

• next